AU2020243431B2 - A2/NY-ESO-1 specific T cell receptors and uses thereof - Google Patents

A2/NY-ESO-1 specific T cell receptors and uses thereof

Info

Publication number
AU2020243431B2
AU2020243431B2 AU2020243431A AU2020243431A AU2020243431B2 AU 2020243431 B2 AU2020243431 B2 AU 2020243431B2 AU 2020243431 A AU2020243431 A AU 2020243431A AU 2020243431 A AU2020243431 A AU 2020243431A AU 2020243431 B2 AU2020243431 B2 AU 2020243431B2
Authority
AU
Australia
Prior art keywords
tcr
cells
seq
cell
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020243431A
Other languages
English (en)
Other versions
AU2020243431A1 (en
Inventor
George Coukos
Melita IRVING
Olivier Michielin
Vincent Zoete
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LUDWIG INSTITUTE FOR CANCER RESEARCH Ltd
Original Assignee
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Cancer Research filed Critical Ludwig Cancer Research
Publication of AU2020243431A1 publication Critical patent/AU2020243431A1/en
Application granted granted Critical
Publication of AU2020243431B2 publication Critical patent/AU2020243431B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
AU2020243431A 2019-03-18 2020-03-17 A2/NY-ESO-1 specific T cell receptors and uses thereof Active AU2020243431B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819988P 2019-03-18 2019-03-18
US62/819,988 2019-03-18
PCT/IB2020/000140 WO2020188348A2 (en) 2019-03-18 2020-03-17 A2/ny-eso-1 specific t cell receptors and uses thereof

Publications (2)

Publication Number Publication Date
AU2020243431A1 AU2020243431A1 (en) 2021-09-30
AU2020243431B2 true AU2020243431B2 (en) 2025-12-18

Family

ID=70465122

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020243431A Active AU2020243431B2 (en) 2019-03-18 2020-03-17 A2/NY-ESO-1 specific T cell receptors and uses thereof

Country Status (6)

Country Link
US (2) US12473346B2 (enExample)
EP (1) EP3941939A2 (enExample)
JP (1) JP7680032B2 (enExample)
CN (1) CN113906140B (enExample)
AU (1) AU2020243431B2 (enExample)
WO (1) WO2020188348A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN116420076A (zh) * 2020-09-27 2023-07-11 基因泰克公司 高通量多参数免疫细胞接合物筛选测定
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
US20240207319A1 (en) 2021-05-06 2024-06-27 Ludwig Institute For Cancer Research Ltd Compositions and methods for immunotherapy
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
EP4374872A1 (en) * 2022-11-22 2024-05-29 Koninklijke Philips N.V. Pde enhanced car-t cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297093A1 (en) * 2007-09-25 2010-11-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Modified t cell receptors and related materials and methods
US20120071420A1 (en) * 2006-09-26 2012-03-22 Immunocore Limited Modified t cell receptors and related materials and methods
WO2017087723A1 (en) * 2015-11-19 2017-05-26 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078334A1 (en) 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
NZ550815A (en) 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
WO2005113595A2 (en) 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2008037943A1 (en) 2006-09-29 2008-04-03 Medigene Limited Cells transformed with nucleic acid encoding ny-eso t cell receptors
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
IL298125A (en) 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
KR102546296B1 (ko) 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
CN108456247A (zh) 2017-02-20 2018-08-28 上海恒润达生生物科技有限公司 靶向ny-eso-1的t细胞受体及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120071420A1 (en) * 2006-09-26 2012-03-22 Immunocore Limited Modified t cell receptors and related materials and methods
US20100297093A1 (en) * 2007-09-25 2010-11-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Modified t cell receptors and related materials and methods
WO2017087723A1 (en) * 2015-11-19 2017-05-26 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBBINS PAUL F ET AL: "Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions", THE JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 180, no. 9, 1 May 2008, pages 6116 - 613 *

Also Published As

Publication number Publication date
JP2022525925A (ja) 2022-05-20
WO2020188348A2 (en) 2020-09-24
US20220152109A1 (en) 2022-05-19
US12473346B2 (en) 2025-11-18
US20260103503A1 (en) 2026-04-16
AU2020243431A1 (en) 2021-09-30
EP3941939A2 (en) 2022-01-26
CN113906140A (zh) 2022-01-07
CN113906140B (zh) 2025-01-28
WO2020188348A3 (en) 2020-12-17
JP7680032B2 (ja) 2025-05-20
CA3134102A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
US20260103503A1 (en) A2/ny-eso-1 specific t cell receptors and uses thereof
JP7846963B2 (ja) 生物学的に関連する直交サイトカイン／受容体対
EP3490585B1 (en) Immunomodulatory polypeptides and related compositions and methods
US12528847B2 (en) Heterodimeric inactivatable chimeric antigen receptors
JP2024069500A (ja) 抗ｇｐｃ３一本鎖抗体を含むｃａｒ
JP2024500847A (ja) 適合可能な受容体特異性を有するキメラ抗原受容体システム
CN109689694A (zh) 与其受体IL-2Rβ结合的白细胞介素-2作为用来增强自然杀伤细胞和调节性T细胞活性的平台
CN112567024A (zh) 表达pd-l1嵌合抗原受体的nk细胞消除pd-l1阳性恶性肿瘤
JP2019516350A (ja) キメラ抗原及びｔ細胞受容体、並びに使用方法
KR20190003938A (ko) 면역치료를 위한 변형된 세포
KR20170068598A (ko) 입양 세포 치료에서 복용을 위한 방법 및 조성물
US12570730B2 (en) Chimeric antigen receptors for direct and indirect targeting of fibronectin-positive tumors
EP3288569A2 (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
JP2023521870A (ja) 改変ｉｌ－１２及びｉｌ－２３ポリペプチドとその使用
CA3031846A1 (en) Chimeric antigen receptor
EP4255922A1 (en) Genetically engineered cells and uses thereof
US20230030680A1 (en) Chimeric gmcsf-il18 receptor
US20230414660A1 (en) Pd-1 decoy variants for immunotherapy
US20250346649A1 (en) Zip cytokine receptors
KR20200056333A (ko) 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법
US20240216427A1 (en) Chimeric antigen receptors targeting splice variants of the extracellular matrix proteins tenascin c (tnc) and procollagen 11a1 (col11a1)
CA3134102C (en) A2/ny-eso-1 specific t cell receptors and uses thereof
HK40058918A (en) A2/ny-eso-1 specific t cell receptors and uses thereof
HK40058918B (en) A2/ny-eso-1 specific t cell receptors and uses thereof
US20240207319A1 (en) Compositions and methods for immunotherapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)